While $34.7 million is a touch more than $34.5 million, that's not exactly huge quarter-over-quarter growth from Seattle Genetics'
Still, investors seem to be shaking off the lackluster growth, and for good reason: Sales of Adcetris -- a drug for treating relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma -- are a very small part of the long-term success of Seattle Genetics.
The light growth seems to be the result of declining business at academic centers, where sales dropped off as patients stopped treatment because they finished their therapy cycles or had a strong enough response to undergo a stem-cell transplant.
The number of community doctors using the drug increased in the second quarter, which is good news for the sales trajectory, as most of the lymphoma patients for whom Adcetris is appropriate are seen in the community setting.
Don't expect much growth in the second half, though; management is guiding for sales of $140 million to $150 million in 2012 -- either flat or a 17% increase from the first half of the year to the second half.
Seattle Genetics lost $12.3 million on a GAAP basis in the quarter but didn't actually burn any cash. In fact, the cash, cash equivalents, and investments increased by $21.5 million during the quarter. I don't know how long investors can expect that to continue, as the biotech is still using product manufactured prior to approval.
Of course, aside from Adcetris, Seattle Genetics can bring in cash by licensing out its antibody-drug conjugate technology, which has attracted some big names, including Roche, GlaxoSmithKline
Internally, Seattle Genetics' future depends on expanding the use of Adcetris into frontline setting for the two lymphomas it's currently approved to treat, as well as other types of cancer. The potential there towers over the $150 million Seattle Genetics will bring in this year.
Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Abbott Laboratories. Motley Fool newsletter services formerly recommended Pfizer. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
3 Dividend Stocks With Better Yields Than PepsiCo
The soft-drink giant offers a solid quarterly dividend, but these three promising businesses will pay you even more to own their shares.
3 Dividend Stocks That Pay You More Than ExxonMobil Does
The oil giant pays its shareholders well, but there are opportunities out there for even higher payouts.
The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past
The big drugmaker had a clear message at the J.P. Morgan Healthcare Conference -- and it's a good one for investors.